Journal of Alzheimers Disease & Parkinsonism
Open Access

Fabien Gosselet
Jean Perrins Faculty
University of Artois-LBHE
France Read
Interview session with Fabien Gosselet

Fabien Gosselet is researcher at the Bloodbrain barrier BBB laboratory directed by Professor Romeo Cecchelli and located at the faculty of Lens France. His Ph.D. thesis in the biggest cancer hospital in Europe the Gustave Roussy Institute in Villejuif France have consisted to characterize involvement of the Bone Morphogenetic Protein BMP signalling pathway in normal human skin keratinocytes and in tumorigenesis processes Since 2006 he has focused his research activity on the physiology of the endothelial cells and pericytes both composing the BloodBrain Barrier in normal and pathological conditions ie Alzheimer disease. Using an original model consisting to cultivate bovine brain capillary endothelial cells with new born rat glial cells his team studies the transport of A Beta peptides across the BBB and the relationship between brain cholesterol metabolism and Alzheimer disease

Fabien has focused his research activity on the Blood brain barrier physiology in normal and pathological conditions, In vitro and in vivo Blood brain barrier models, Transport of molecules across the Blood brain barrier, Astroglia endothelial interrelations, Cerebral cholesterol metabolism and Blood brain barrier, Biochemistry and signaling pathways at the BBB level, Skin homeostasis and cancerology.

1.How many years have you been associated with the current research?
8 years

2.What is the research topic you are working on now?
Role of the blood-brain barrier (BBB) in Alzheimer’s disease. Influence of the diet on the BBB physiology and in neurodegenerative diseases.

3.What are attributes for a quality article?
Rigor in the analysis and the interpretation of the results, relevance in the cellular/animal models used. Original hypothesis. Adequate controls/protocols used.

4.Do you have any research funding (NIH or other national funding) now?
Grants from my University and from the French foundation against Alzheimer’s disease, grants from industrial partners.

5.When did you become an editor of OMICS Journal?
Since the beginning of the JADP, in 2010.

6.Where can the journal find the maximum scope in terms of niche?
In congress

7.What is your greatest career accomplishment?
In few months, I will be laboratory director.

8.How does the published scientific content assist the potential researchers?
For me, the published scientific content is the scientific publications. I think that these latter allow researchers to get in touch with new technologies, new animal/cellular models, new hypothesis, or novel drugs to test.

9.What is the purpose of serving as an editor?
Reviewing some papers, soliciting some other reviewers, having a direct impact on the policy of the journal. Advertising for the journal and strongly encourage other researchers to publish in the journal.

10.Do you have any patents?
None

11.Have you contributed any editorials or papers (any types) to OMICS Journals in the
past two years?
Yes.

12.Do you plan to contribute any editorials or papers to OMICS Journals in the next year?
Yes.

13.How would you define your experience with OMICS Group?
Very nice. Efficient and Fast reviewing process.

14. Your opinion on conducting Editorial Board meetings at related Conferences?
None

15.Would you recommend OMICS to your friends or colleagues?
Yes.

16.How do you differentiate Journal of Alzheimer’s Disease & Parkinsonism with other journals in the field?
JADP is an open access journal with a worldwide readership allowing a large and efficient
diffusion of the results and therefore reinforcing the impact of published work. High quality
of members of the editorial board provides rigorous and rapid peer review process.